SC-2004 is our lead oral GLP-1R agonist, developed using our proprietary method of fine-tuned receptor modulation.
Treated animals have shown an average weight loss of 16% after just 2 weeks of daily dosing along with a significant reduction in food intake and normalization of hyperglycemia.
Most importantly, the molecule is safe and well tolerated with no adverse side effects observed.
SC-2004 represents our efforts to develop a widely available, easily manufactured oral therapeutic that maintains the therapeutic benefits of GLP-1 receptor modulation with enhanced tolerability, safety, convenience, and broad efficacy.
